Nam D. Kim
Incheon, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications
Gut microbiota-derived isoxanthohumol metabolite, 8-prenylnaringenin, mitigates endothelial dysfunction in Angiotensin II-induced hypertension through G protein-coupled estrogen receptor-mediated eNOS activation.
Journal: Biochemical pharmacology
Published: November 24, 2025
Piperidinesulfonyl derivatives, novel CYP4A inhibitors, ameliorate hepatic lipotoxicity in metabolic dysfunction-associated steatotic liver disease.
Journal: Biochemical pharmacology
Published: August 11, 2025
Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var.
Journal: Nature communications
Published: June 03, 2025
Correction: Nam et al. Identification of Thiazolo[5,4-b]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance. Cancers 2023, 15, 143.
Journal: Cancers
Published: May 22, 2024
Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease.
Journal: Clinical and translational medicine
Published: December 01, 2023
Identification of α-amanitin effector proteins in hepatocytes by limited proteolysis-coupled mass spectrometry.
Journal: Chemico-biological interactions
Published: June 29, 2023
Sesamin ameliorates lipotoxicity and lipid accumulation through the activation of the estrogen receptor alpha signaling pathway.
Journal: Biochemical pharmacology
Published: June 28, 2023
p21-activated kinase 4 suppresses fatty acid β-oxidation and ketogenesis by phosphorylating NCoR1.
Journal: Nature communications
Published: February 02, 2023
p21-activated kinase 4 counteracts PKA-dependent lipolysis by phosphorylating FABP4 and HSL.
Journal: Nature metabolism
Published: November 16, 2022
Last Updated: 09/26/2026